

AD _____

GRANT NUMBER DAMD17-94-J-4441

TITLE: Initiation of Breast Cancer by Endogenous Estrogens:
Mechanism and Prevention

PRINCIPAL INVESTIGATOR: Jack Fishman, Ph.D.

CONTRACTING ORGANIZATION: Cornell University Medical Center
New York, New York 10021

REPORT DATE: March 1997

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970711 113

DTIC QUALITY INSPECTED 8

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE March 1997	3. REPORT TYPE AND DATES COVERED Final (1 Aug 94 - 31 Jan 97)	
4. TITLE AND SUBTITLE Initiation of Breast Cancer by Endogenous Estrogens: Mechanism and Prevention			5. FUNDING NUMBERS DAMD17-94-J-4441	
6. AUTHOR(S) Jack Fishman, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cornell University Medical Center New York, New York 10021			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Both endogenous and environmental factors are thought to contribute to cancer of the breast. Among these, estrogens have attracted intense interest for decades, but the mechanisms by which this class of hormone mediate normal and neoplastic growth have remained obscure. We provide in vitro data to support the hypothesis that 16 α -hydroxyestrone (16 α -OHE ₁) is unique among estrogens with regard to its transforming properties in mammary cells. This suggests that the pathway leading to the formation of 16 α -OHE ₁ may be a determinant of mammary carcinogenesis, either because of genetic variation at this locus or because the locus is differentially regulated in healthy women and women with breast cancer. We have identified <i>Cyp2d-13</i> as a putative mediator of this pathway in mice. This represents a crucial advance in our efforts to adjudicate the hypothesis that estrogen metabolism is a critical factor in breast cancer. Expression of <i>Cyp2d-13</i> is remarkably associated with the tumor phenotype in the mouse mammary gland. With regard to the human CYP2D6 locus, it is very intriguing that such a polymorphic locus might be linked to breast cancer. Ultimately, CYP2D6 genotyping might serve to identify those individuals who might most benefit from dietary or pharmacological strategies which induce the competing, 2-hydroxylase pathway.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 36	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

Date

DTIC QUALITY INSPECTED 8

TABLE OF CONTENTS

	Page Number
Abstract	2
Foreword	3
Introduction	5
Purpose of the research	5
Background of previous work	5
Body	8
Altered E2 metabolism in myc-transformed cells	8
Estrogen responsiveness of myc-transformed cells	9
Modulation of E2 metabolism and proliferation in MCF-7 cells	9
In vitro models examining the role of estrogens in mammary carcinogenesis	10
Identification of a potential estrogen 16 α -hydroxylase selectively elevated in mammary tumors	10
Development of <i>Cyp2d-13</i> -specific antisera	12
A novel CYP2D6 haplotype in C16 α -hydroxylating human mammary cells	13
Conclusion	15
References	16
Appendix (containing tables and figures)	20

INTRODUCTION

Purpose of the research

Both endogenous and environmental factors are thought to contribute to cancer of the breast. Among these, estrogens have attracted intense interest for decades, but the mechanisms by which this class of hormone mediate normal and neoplastic growth have remained obscure. Epidemiological and biochemical data indicate that 16 α -hydroxyestrone (16 α -OHE₁) is unique among estrogens with regard to its transforming properties in mammary cell lines and its association with breast cancer in women. This suggests that the pathway leading to the formation of 16 α -OHE₁ may be a determinant of mammary carcinogenesis, either because of genetic variation at this locus or because the locus is differentially regulated in healthy women and women with breast cancer. **The purpose of our work has been to employ cellular and molecular approaches which elucidate the mechanisms by which 16 α -OHE₁ exerts its unique effects on estrogen receptor function.** However, because the proximate cause of increased 16 α -OHE₁ in individuals is most likely due to increased levels of estrogen 16 α -hydroxylase activity, we felt it very prudent to expand our approach. Thus, **we have also sought to examine the role of estrogen metabolism in breast cancer by characterizing genes which 16 α -hydroxylate estrogens.**

Background

Estrogen metabolism and breast cancer

Estrogens are metabolized in a complex fashion (fig. 1), with different pathways having markedly divergent effects on the proliferative state of mammary epithelial cells (1). The clinical significance of these distinct metabolic pathways is suggested by the observation that a relative increase in the estrogen metabolite 16 α -hydroxyestrone (16 α -OHE₁) is unique among estrogens in its association with breast cancer in women. Estrogen 16 α -hydroxylase activity is selectively elevated both in post-menopausal women with breast cancer (2) and in women at risk for breast cancer (2) whereas the competing 2-hydroxylation and 17-ol oxidation pathways are not. Moreover, the degree of 16 α -hydroxylation is influenced by certain dietary and environmental components, which correspondingly alter the relative risk for breast cancer in parallel fashion. Estrogen 16 α -hydroxylase activity has also been found to be elevated in strains of mice with increased susceptibility to breast cancer (3).

These epidemiological observations have prompted a closer analysis of estrogen metabolism within the context of mammary carcinogenesis. Remarkably, these studies have consistently established a positive relationship between breast cancer and elevated 16 α -hydroxylation in mammary ductal epithelium. For example, mammary explants from breast cancer-prone strains of mice are about 5 times more active than explants from low risk strains at 16 α -hydroxylating estrogens (4). In liver cultures,

however, no such difference is seen. In nontumorous tissue from breast cancer patients, the increased activity has been specifically detected in the terminal duct lobular units (5), the presumed origin of ductal carcinoma which represents about 80% of all human breast cancer.

Cell culture models provide additional evidence to suggest a unique role for paracrine- or autocrine-derived 16α -OHE₁ in breast cancer. Cellular 16α -hydroxylase activity closely parallels the tumorigenic potential of mammary cell lines in nude mice (6). By the same token, exogenously added 16α -OHE₁ routinely stimulates cellular and molecular changes characteristic of transformation. For example, while 16α -OHE₁ and other estrogens demonstrate a comparable ability to accelerate the proliferation of mammary cells over time, only 16α -OHE₁-treated cells are able to maintain this growth rate upon withdrawal of the hormone (7). In addition, 16α -OHE₁ dramatically induces anchorage-independent growth and DNA repair in C57/MG mouse mammary epithelial cells (7, 8). The induction is comparable to that obtained with the mammary carcinogen DMBA, while estradiol and estriol are without effect. Several molecular changes occur in parallel with these events in 16α -OHE₁-treated cells: the formation of estrogen receptor and progesterone receptor is markedly diminished, while the levels of myc, fos, jun and neu are elevated (7) (our unpublished observations).

The affinity of 16α -OHE₁ for the estrogen receptor is relatively low when compared with estradiol. How, then, might this hormone achieve such a profound impact on the mammary epithelium? One clue may be that, among estrogens, 16α -OHE₁ has the unique ability to form covalent adducts with primary amines. This occurs nonenzymatically through a Schiff base formation and subsequent Heyns rearrangement (9). Such a mechanism could account for the observed propensity of 16α -OHE₁ to form DNA adducts (10) and irreversibly bound complexes with the estrogen receptor (11). Both of these events represent possible, yet unproven, explanations the unique growth-promoting effects of 16α -OHE₁. Given these properties, the formation of 16α -OHE₁ and its possible relationship to breast cancer is very reminiscent of the metabolism of xenobiotics to proximate carcinogens by certain CYP species.

P450 enzymes in steroid metabolism

Estrogen 16α -hydroxylase activity in mice and humans demonstrates apparently genetic and tissue-specific properties which could be very efficiently analyzed by a molecular biological approach. While the gene(s) responsible for this activity have remained uncharacterized, the very nature of this hydroxylation reaction implies that it is mediated by a cytochrome P450 species.

The superfamily of cytochrome P450 (CYP) genes encodes a vast number of structurally similar, **broad-specificity** enzymes that metabolize drugs, plant metabolites, environmental pollutants and endogenous steroids to forms which can then be further modified and excreted (12). Additionally, several P450 family members mediate **highly specific** reactions that participate in steroid hormone synthesis. The superfamily of CYP genes

is so ancient that it predates drugs and plant-animal interactions, implying that these so-called "drug-metabolizing" enzymes have an evolutionarily conserved role in regulating the levels of endogenous molecules that control basic homeostatic functions of the organism (13). More than 200 CYP genes have been isolated from 42 species (12). On the basis of sequence similarity and genomic structure, these have been divided into 36 families, 12 of which exist in all mammals examined to date. Some families have been further subdivided into subfamilies, which typically correspond to clusters of tightly linked genes. For example, the CYP2 family has been subdivided into CYP2A, CYP2B, CYP2C, CYP2D, etc. By convention, genes encoding human and rat P450 enzymes are prefaced in capital letters (CYP) while the P450-encoding genes in mice are indicated by an italicized prefix (*Cyp*).

Over the last decade, there has been a vast effort to characterize the catalytic functions of individual P450 enzymes, using either biochemically purified preparations or heterologous expression systems with cloned cDNAs. With regard to metabolism of endogenous steroids, the primary (if not sole) P450 families mediating these activities appear to be CYP 1, 2 and 3. Leaving aside the considerable xenobiotic-metabolizing functions of these families for the moment, the CYP 1 family members identified to date exclusively hydroxylate estrogens. CYP1A1 and CYP1A2 contain significant 2-hydroxylase activity (14-17), while CYP1B1 appears to be a major 4-hydroxylase (18). At the other end of the spectrum, CYP3 genes encode P450 enzymes with remarkably diverse steroid-metabolizing abilities. For example, human CYP3A4, which is the predominant hepatic P450 under normal circumstances, is an efficient metabolizer of estradiol, progesterone, testosterone, DHEA-sulfate and cortisol (19). CYP2 enzymes comprise an intermediate functional state; the family as a whole metabolizes most steroids, but some of the individual family members are relatively specific in their activity. For example, *Cyp2d-9* exhibits a quite specific testosterone 16 α -hydroxylase activity (20). Remarkably, none of the CYP genes cloned to date has been shown to encode an estrogen 16 α -hydroxylase activity, although a partially purified CYP2D from rat liver can mediate this reaction (21).

We have utilized a PCR-based approach to search for CYP genes which mediate the 16 α -hydroxylation of estrogens. Our evidence, described in detail in "The Body of Completed Research" below, provides strong evidence in support of the hypothesis that a novel, mammary tumor-associated P450, termed *Cyp2d-13*, may mediate this activity. Conclusive evidence of this hypothesis will ultimately permit us to test directly whether aberrant expression of this gene leads to mammary carcinogenesis.

BODY OF COMPLETED RESEARCH

This section has been divided into 7 parts. The first four of these summarize our continued efforts pertaining to the biochemical and cellular aspects of estrogen 16 α -hydroxylation and its relationship to tumorigenesis. The last three parts describe our isolation and characterization of *Cyp2d-13*, along with its relationship to estrogen 16 α -hydroxylation and the tumor phenotype.

Altered E₂ metabolism in myc-transformed mouse mammary epithelial cells

Our previous studies on immortalized, tumorigenic murine mammary epithelial cell lines have demonstrated that exposure to chemical carcinogens or transfection with oncogenes results in induction of hyperproliferation as evidenced by anchorage-independent growth (AIG) *in vitro* prior to mammary fat pad or subcutaneous transplantation (22). The experiment shown in table AT-1 was performed to examine whether the relative extent of AIG corresponds with the degree of transformation in the parental MMEC, oncogene-initiated MMEC/myc3 and oncogene-transformed MMEC/myc3-Pr1 cells. The AIG assay revealed a progressive increase in anchorage-independent colonies formed by MMEC/myc3 and MMEC/myc3-Pr1 cells and a positive correlation with tumorigenicity *in vivo*. The parental MMEC cells, however, were negative in the AIG and tumorigenicity assays. These results suggest that AIG may represent a valid cellular marker for preneoplastic and neoplastic transformation of mammary epithelial cells.

The experiment presented in table AT-2 was conducted to examine whether c-myc oncogene-induced tumorigenic transformation influences the cellular metabolism of E₂ and steroid receptor status. The relative extent of E₂ metabolism was determined by the radiometric assay measuring C2-hydroxylation and C16 α -hydroxylation of E₂. The data is expressed as the ration of C2/C16 α -hydroxylation. The relative extent of estrogen receptor (ER) and progesterone receptor (PR) proteins was determined using the dextran-coated charcoal (DCC) assay. The C2/C16 α ratio exhibited a progressive decrease in MMEC/myc3 and MMEC/myc3-Pr1 cells relative to that observed in MMEC cells. The observed decrease in the ratio was due to an increase in C16 α -hydroxylation and concomitant decrease in C2-hydroxylation (data not shown). Consistent with the alteration in cellular metabolism of E₂, ER protein levels also decreased in MMEC/myc3 and MMEC/myc3-Pr1 cells relative to those in MMEC cells. By contrast, PR levels increased in MMEC/myc3 cells but not in MMEC/myc3-Pr1 cells. These results suggest that overexpression of c-myc may induce aberrant hyperproliferation in part by downregulating hormone responsiveness in mammary epithelial cells.

Estrogen responsiveness of myc-transformed mammary epithelial cells

The conventional determinants for estrogen response include: E_2 -mediated initiation of replicative DNA synthesis, expression of early response genes, ER and PR upregulation, peptide growth factor expression and reversible inhibition of growth by antiestrogens. In addition, oxygenated metabolites of E_2 generated via P450 hydroxylases have been shown to exert direct effects on hormone responsive target tissue (7, 8). Our earlier observation that constitutive overexpression of c-myc confers aberrant hyperproliferation and partial abrogation of serum-derived growth factor requirement prompted us to examine the extent of E_2 metabolism and degree of E_2 responsiveness in MMEC/myc3-Pr1 cells.

As summarized in table AT-3, MMEC/myc3-Pr1 cells were incubated with 10 nM E_2 for 96 hours and the culture medium was used for product isolation and identification by gas chromatography and mass spectrometry (GC/MS). These data clearly demonstrate that the cells were capable of converting E_2 into estrone (E_1), 16α -OHE₁, 2-OHE₁ and estriol. These results, when combined with data obtained by radiometric analysis, strongly support the contention that mammary epithelial cells in culture retain the ability to metabolize E_2 .

The persistence of E_2 responsiveness in MMEC/myc3-Pr1 cells was examined by determining whether E_2 can upregulate growth and increase ER content in these cells. Table AT-4 indicates that a continuous 5-day exposure to E_2 resulted in a dose-dependent increase in cell number and levels of ER protein. These effects occurred at physiological levels (1-10 nM) of hormone.

Modulation of E_2 metabolism and proliferation in MCF-7 cells

Our earlier studies on the murine mammary epithelial cell culture systems have shown that prototypic initiators of tumorigenesis (chemical carcinogens and oncogenes) results in decreased ratio of C2/C16 α -hydroxylation of E_2 and increased aberrant hyperproliferation (8). These biochemical and cellular perturbations are reversed by the presence of known inhibitors of mammary carcinogenesis (23). The experiment shown in table AT-5 was designed to validate E_2 metabolism and hyperproliferation as markers for human mammary carcinogenesis. The extent of alteration in 2-OHE₁ formation as an endpoint for E_2 metabolism, and in AIG as an endpoint for aberrant hyperproliferation was measured in MCF 7 cells treated with the tumor inhibitors indole-3-carbinol (I3C), tamoxifen (TAM) and 4-hydroxytamoxifen (4-OHTAM).

Treatment with either I3C or 4OHTAM stimulated the formation of 2-OHE₁ inhibiting the extent of AIG. Since direct addition of 2-OHE₁ also inhibited AIG, this suggests that 4-OHTAM may act in part by inducing 2-OHE₁. TAM also inhibited AIG (to a lesser extent than 4-OHTAM), but had no effect on 2-hydroxylation. We therefore propose that the tamoxifen metabolite 4-OHTAM functions both by acting as a receptor antagonist and by altering estrogen metabolism, and that both mechanisms are required for its full antiproliferative effect.

In vitro models examining the role of estrogens in mammary carcinogenesis

In vitro models derived from mammary explant and cell culture systems provide an innovative approach to examining the effects of exogenous agents on the process of mammary carcinogenesis and its modulation directly at the level of the target tissue (22,23). Experiments conducted on murine mammary explant culture systems have shown that treatment of the non-involved mammary tissue to chemical carcinogens results in increased carcinogen-DNA binding, enhanced C16 α -hydroxylation of E₂ and high incidence of mammary hyperplasia *in vitro*, prior to tumorigenicity *in vivo*. Independent studies using the epithelial cell culture model have also shown that treatment with carcinogens or transfection with oncogenes results in upregulation of some biochemical and cellular endpoints (8). Thus, both of these *in vitro* models provide strong evidence that perturbed biochemical and cellular events occurring prior to tumor formation represent reasonable markers for preneoplastic transformation.

We therefore used murine and human explant cultures to examine the relationship between estrogen 16 α -hydroxylation and risk of breast cancer (Table AT-6). Remarkably, E₂ C16 α -hydroxylation was 3- to 4-fold higher in explants from the high risk groups when compared to the corresponding low risk groups. In addition, explants from the high-risk groups exhibited a greater response to carcinogen-induced perturbation of E₂ C16 α -hydroxylation (data not shown). These data indicate that estrogen 16 α -hydroxylation represents a biochemical marker for endocrine responsiveness whose alteration may predict the susceptibility of the target tissue to carcinogenesis.

We next examined whether C16 α -hydroxylated metabolites of E₂ may act as initiators of mammary carcinogenesis (Table AT-7). Various metabolites were tested for their ability to influence unscheduled DNA synthesis (a marker for genotoxicity) and anchorage-independent growth (a marker for aberrant proliferation). Among the metabolites tested, 16 α -OHE₁ exhibited a clearly superior ability to induce these markers. Indeed, the effects of 16 α -OHE₁ rivaled those of the classical mammary carcinogen DMBA.

Identification of a potential estrogen 16 α -hydroxylase selectively elevated in mammary tumors

The conserved nature of selected regions in CYP families permitted the use of a PCR-based approach to search for CYP genes encoding enzymes with estrogen 16 α -hydroxylase activity. We used degenerate primers specific for CYP families 1, 2, or 3 because most steroid-metabolizing P450 enzymes fall within one of these families (see above). All primer sets were designed to span at least one intron in order to avoid potential confusion from contaminating genomic DNA. As template for PCR, we used cDNA

derived from mouse T₁Pr₁ and human MCF-10F cells, which contain high levels of estrogen 16 α -hydroxylase activity (;unpublished observations).

Two sets of degenerate primers (specific for families 1 or 2) successfully amplified fragments of the correct size, using T₁Pr₁ cDNA as template. Because these fragments may be heterogeneous, we subcloned them into the vector pGEM-T (Promega) and sequenced numerous clones. For family 1, all clones analyzed thus far correspond to CYP1A2, which is a stronger estrogen 2-hydroxylase than CYP1A1. This is somewhat surprising, because previous reports had indicated that CYP1A1, but not CYP1A2, is expressed in human MCF-7 cells (24). Our primers amplify CYP1A1, CYP1A2 and CYP1B1 with similar efficiency; hence we currently have no explanation for the distinct expression of CYP1A species. In any event, since CYP1A2 does not 16-hydroxylate estrogens, and no other CYP1 PCR fragments have been detected in our analysis to date, we have adopted the working hypothesis that the 16 α -hydroxylase is not a CYP1 family member.

Using the family 2 primers and T₁Pr₁ cDNA as template, we amplified a particularly strong DNA fragment of the correct size. Sequencing data from 16 subclones and restriction enzyme analysis of the uncloned PCR fragment indicates that the amplified product is homogeneous and corresponds to a novel mouse *Cyp2d-13* family member (provisionally termed *Cyp2d-13*). This PCR product has been used to obtain full-length cDNAs corresponding to *Cyp2d-13* (fig. 2). *Cyp2d-13* exhibits several features which suggest that it is indeed a 16 α -hydroxylase. The sequence of *Cyp2d-13* is most similar to *Cyp2d-9*, which 16 α -hydroxylates testosterone, and rat CYP2D4, which is not a 16 α -hydroxylase but has been shown to cross-react with antisera directed against a purified P450 preparation with estrogen 16 α -hydroxylase activity (fig 3). This observation alone is rather provocative.

A comparison of the predicted amino acid sequence of *Cyp2d-13* and other *Cyp2d* family members suggests that their functional differences might primarily be in relation to substrate specificity (fig. 4). Substrate specificity in the CYP2D family appears to be conferred at least in part by 6 small, dispersed regions, termed substrate recognition sites (SRS). SRSs in the CYP2 family have been determined by aligning CYP2 sequences with CYP101A (P450cam) (25), whose substrate recognition sites (SRSs) have been identified conclusively by X-ray crystallography. Mutagenesis and domain-swapping experiments with a number of CYP2 genes have been entirely consistent with the proposed SRS regions. It is important to emphasize here that SRSs appear to determine substrate specificity rather than enzymatic activity. For example, a single amino acid substitution in SRS-5 of rat CYP2D1 (Ile380→Phe) results in decreased catalytic activity toward bufuralol but not debrisoquine (26), suggesting that the enzymatic function of the protein has remained intact. In the partial alignment shown in figure 4, note that the predicted amino acid sequence of *Cyp2d-13* diverges from other *Cyp2d* subfamily members primarily in two small regions that correspond to SRS-5 and SRS-6.

To obtain further evidence that *Cyp2d-13* might represent an estrogen 16 α -hydroxylase, we used a quantitative RT-PCR approach (27) to examine *Cyp2d-13* expression in different mammary cell lines with more than 20-

fold variation in their enzymatic activity. Unlike Northern or RNase Protection analyses, which would likely suffer from significant cross-hybridization with other *Cyp2d* members, here we were able to use primers completely specific for *Cyp2d-13*. SP1 primers were used as an internal control. We found that *Cyp2d-13* RNA levels are very high in tumor-derived RIII/Pr1 cells, but barely detectable in MMEC and RIII/MG cells (derived from normal mouse mammary epithelium) (fig. 5). This is in excellent agreement with the relative ability of these cells to 16 α -hydroxylate estrogens. We also found that the mammary carcinogen dimethylbenz[a]anthracene (DMBA) induces *Cyp2d-13* by roughly 2-fold in T₁Pr₁ cells and several other mouse mammary cell lines (not shown). This correlates well with previously observed effects of DMBA on estrogen 16 α -hydroxylase activity (28).

Cyp2d-13 expression correlates with both C16 α -hydroxylation and the tumorigenicity of the above cell types. Interestingly, this association is also true in primary mouse mammary tumors, where *Cyp2d-13* RNA levels are much higher than in the normal mammary gland (fig. 5). We also examined the expression pattern of *Cyp2d-13* in a panel of normal mouse tissues. Only liver contained appreciable levels of this P450 species, but most tissues did express *Cyp2d-13* at very low levels (fig. 6). These observations are consistent with previously published data showing that estrogen 16 α -hydroxylase activity is normally mainly in the liver but strongly increased in mammary tumor tissue (4).

Development of *Cyp2d-13*-specific antisera

The foregoing observations would be strengthened by a corresponding analysis of P450 2d-13 protein levels. Moreover, the availability of antisera which inhibit P450 2d-13 function would be a valuable tool for testing whether this enzyme mediates estrogen 16 α -hydroxylase activity in liver and mammary tumor samples. Because of the high degree of homology between *Cyp2d-13* and other *Cyp2d* species, we chose a peptide-based strategy to generate specific antisera. We synthesized two peptides corresponding to SRS-1 (SQGIVLARYGPAC) and SRS-5 (LPLGVPHKTSRDIEC) because these regions of P450 2d-13: (1) should be on the surface of the protein based on alignment with bacterial P450 enzymes whose structures have been resolved (2), (2) correspond to presumptive substrate-binding regions and therefore may generate antisera with immuno-inhibitory properties toward enzymatic function, and (3) contain some residues not conserved in other P450 2d family members (9/12 residues match SRS-1 in P450 2d-9 and 7/14 residues match SRS-5 in P450 2d-9). A cysteine residue was added at the C-terminus of each peptide to permit coupling to a carrier protein (KLH) for immunization in rabbits.

To evaluate the specificity of the antisera, we used a transient expression assay in human embryonic kidney 293T cells. These cells transfect at very high efficiency and permit potent expression of cDNA clones controlled by the cytomegalovirus (CMV) promoter (A.M.C. Brown, personal communication). We generated CMV-driven expression plasmids

containing *Cyp2d-13*, *Cyp2d-9*, or human CYP1A1, each with the coding sequence for a unique "FLAG" epitope (29) at the C-terminus of the indicated P450. A monoclonal antibody highly specific for this epitope is commercially available (Eastman Kodak); this can be used to demonstrate that transfection of each expression plasmid results in similar levels of protein expression. Transfection of 293T cells with a CMV-*Cyp2d-13*/FLAG expression plasmid and subsequent immunostaining with either the monoclonal FLAG antibody or an SRS-1 antiserum (termed 422) results in intense staining of a subpopulation of cells (see figure 7A, 7B), while cells transfected with the "empty" CMV expression plasmid are not stained by either antiserum (figure 7C, 7D). Preimmune 422 serum did not stain transfected cells (not shown). An SRS-5 antiserum (399) also caused intense staining of CMV-*Cyp2d-13*/FLAG-transfected cells (not shown).

Transfected 293T cells seemed to express P450 2d-13 at such high levels that the cells became "overloaded". There was not a clear microsomal localization as would be expected, but rather an enormous inclusion body-like appearance. The stained cells also possessed an irregular morphology when compared to their nontransfected neighbors. Therefore, we used another cell line, termed COS-1, which has been used extensively as a vehicle for analyzing the functional activities of cloned CYP genes. CMV-*Cyp2d-13*/FLAG-transfected COS-1 cells give a typical microsomal staining pattern (figure 7E). Remarkably, transfection of COS-1 cells with the *Cyp2d-9* or CYP1A1 containing expression plasmids did not result in significant staining with the 422 antiserum (not shown), indicating that this antiserum is highly specific for P450 2d-13.

Cyp2d-13 is expressed at much higher levels in RIII/Pr1 cells than in MMEC cells. Thus, to determine whether our antisera could detect endogenously expressed P450 2d-13, we stained these cells with the 422 antiserum (figure 8). The perinuclear microsomal region of RIII/Pr1 cells were intensely stained with this antiserum (figure 8A, 8B), while MMEC cells gave no staining whatsoever (figure 8C).

All of the above data has also been corroborated by immunoblot analysis (not shown). In sum, our data strongly suggest that the SRS-1- and SRS-5-directed antisera should be excellent tools for examining *Cyp2d-13* expression and may very well be appropriate for future immuno-inhibition studies.

A novel CYP2D6 haplotype in C16 α -hydroxylating human mammary cells

Collectively, the above observations give considerable weight to the hypothesis that *Cyp2d-13* may be a bona fide estrogen 16 α -hydroxylating enzyme in mouse mammary tissue. This hypothesis is further supported by our PCR analysis in human MCF-10F cells, which has also selectively detected CYP2D expression. As in mice and rats, the human CYP2D locus on chromosome 22 has multiple tightly linked members, but only CYP2D6 appears to be expressed (30,31). The CYP2D6 locus is highly polymorphic, resulting in marked variations in the metabolism of certain commonly prescribed drugs (32). CYP2D6 polymorphisms have therefore been of

intense pharmacological interest. There are four characterized variant CYP2D6 alleles which collectively account for the poor ability of 5-10% of Caucasians to metabolize debrisoquine and numerous related plant alkaloids (33, 34). Additionally, at least two distinct haplotypes are associated with the "extensive metabolizer" phenotype (fig. 9) (35). One of these, termed CYP2D6L, is occasionally amplified in some families, resulting in their ability to metabolize certain drugs at an "ultra-rapid" rate (36). Enzymatic reactions mediated by CYP2D6 are therefore prone to wide inter-individual variation.

Sequence analysis of the CYP2-derived PCR fragment in MCF-10F cells indicates the presence of a previously undescribed CYP2D6 haplotype (which we have termed CYP2D6M). This haplotype contains a cluster of variant bases, resulting in the deletion of Val386 and two nearby, unconserved amino acid changes (fig. 9). Similar to the above observations with *Cyp2d-13*, these changes occur in the region corresponding to SRS-5, which helps determine substrate specificity in other CYP2 family members. Indeed, the substrate specificity of SRS-5 has been demonstrated experimentally using rat CYP2D1 (26), which is orthologous to CYP2D6. MCF-7 cells, which possess little C16 α -hydroxylase activity, do not contain the CYP2D6M haplotype. We are currently characterizing this haplotype in full, after which we will engage in a comparative analysis of estrogen-metabolizing ability amongst the various CYP2D6 polymorphisms. Should this approach prove fruitful, it will ultimately be of great interest to examine the association of these polymorphisms with breast cancer.

CONCLUSIONS

Consistent with previous studies, myc oncogene transformation of mammary epithelial cells leads to induction of C16 α -hydroxylation, anchorage-independent growth and tumorigenesis. Agents which specifically reduce C16 α -hydroxylation (e.g. indole-3-carbinole) inhibit hyperproliferation such as that observed here; moreover, ER antagonists such as tamoxifen only achieve their full inhibitory effect when converted to metabolites (4-OHTAM) that also reduce C16 α -hydroxylation. These data support our hypothesis that this pathway of estrogen metabolism leads to the formation of estrogens that promote mammary tumorigenesis. Indeed, we observed that 16 α -OHE₁ was unique among estrogens in its ability to stimulate genotoxic damage and anchorage-independent growth in C57/MG cells.

Our efforts to identify precisely the molecular changes which occur when mammary cells are chronically exposed to 16 α -OHE₁ have been severely hampered by difficulties in growing MCF-7 cells long-term in culture in steroid-depleted medium and the prolonged process of moving the laboratory to a new location. However, we have made extensive progress in the characterization of mouse and human genes that may mediate the formation of 16 α -OHE₁. We soon expect to have confirmation of this by heterologous expression of the cloned cDNAs, in which case we will be able to utilize less problematic molecular approaches (stable transfection, transgenics) to approach these experiments.

The identification of *Cyp2d-13* as a putative estrogen 16 α -hydroxylase is a crucial advance in our efforts to adjudicate the hypothesis that estrogen metabolism is a critical factor in breast cancer. Expression of *Cyp2d-13* is remarkably associated with the tumor phenotype in the mouse mammary gland; moreover, the gene possesses many of the features expected of a bona fide estrogen 16 α -hydroxylase. With regard to the human CYP2D6 locus, it is very intriguing that such a polymorphic locus might be linked to breast cancer. Ultimately, CYP2D6 genotyping might serve to identify those individuals who might most benefit from dietary or pharmacological strategies which induce the competing, 2-hydroxylase pathway.

REFERENCES

1. Bradlow HL. *Metabolic approach to the induction of antiestrogenic action.* in *Annual Meeting of the American Society for Preventive Oncology.* 1992. Bethesda, MD:
2. Schneider J, Kinne DW, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J 1982 Abnormal oxidative metabolism of estradiol in women with breast cancer. *Proc Natl Acad Sci USA* 79:3047-3051
3. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J 1985 Estrogen 16 α -hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. *Proc Natl Acad Sci USA* 82:6295-6299
4. Telang NT, Bradlow HL, Kurihara H, Osborne MP 1989 *In vitro* biotransformation of estradiol by explant cultures of murine mammary tissues. *Breast Cancer Res Treat* 13:173-181
5. Osborne MP, Bradlow HL, Wong GY, Telang NT 1993 Up regulation of estradiol C16 α -hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. *J Natl Cancer Inst* 85:1917-1920
6. Telang NT, Narayanan R, Bradlow HL, Osborne MP 1991 Coordinated expression of intermediate biomarkers for tumorigenic transformation in RAS-transfected mouse mammary epithelial cells. *Breast Cancer Res Treat* 18:155-163
7. Swaneck GE, Fishman J 1991 Effects of estrogen on MCF-7 cells: positive or negative regulation by the nature of the ligand-receptor complex. *Biochem Biophys Res Commun* 174:276-281
8. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL 1992 Induction by estrogen metabolite 16 α -hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. *J Natl Cancer Inst* 84:633-638
9. Miyairi S, Ichikawa T, Nambara T 1991 Structure of the adduct of 16 α -hydroxyestrone with a primary amine: evidence for the Heyns rearrangement of steroidal D-ring α -hydroxyimines. *Steroids* 56:361-366
10. Bucala R, Fishman J, Cerami A 1984 The reaction of 16 α -hydroxyestrone with erythrocytes in vitro and in vivo. *Eur J Biochem* 140:593-598
11. Swaneck GE, Fishman J 1988 Covalent binding of endogenous estrogen 16 α -hydroxyestrone to estradiol receptor in human breast cancer

cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 85:7831-7835

12. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW 1993 The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1-51

13. Nebert DW 1991 Proposed role of drug-metabolizing enzymes: Regulation of steady-state levels of the ligands that effect growth, homeostasis, differentiation and neuroendocrine functions. Mol Endocrinol 5:1203-1214

14. Dannan GA, Porubek DJ, Nelson SD, Waxman DJ, Guengerich FP. 17 β -estradiol 2- and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: roles of individual forms, inductive effects, developmental patterns, and alterations by gonadectomy and hormone replacement. Endocrinology 1986;118:1952-1960.

15. Ball SE, Forrester LM, Wolf CR, Back DJ 1990 Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α -ethinyloestradiol. Biochem J 267:221-226.

16. Aoyama T, Korzekwa KR, Nagata K, Gillette J, Gelboin HV and Gonzalez FJ 1990 Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 126: 3101-3106.

17. Spink DC, Eugster H-P, II DWL, Schuetz JD, Schuetz EG, Johnson JA, Kaminsky LS, Gierthy JF 1992 17 β -estradiol hydroxylation catalyzed by human cytochrome P4501A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 293:342-348

18. Spink DC, Hayes CL, Young NR, Christou M, Sutter TR, Jefcoate CR and Gierthy JF 1994 The effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 beta-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol 51:251-258.

19. Brian WR, Sari M-A, Iwasaki M, Shimada T, Kaminsky LS and Guengerich FP 1990 Catalytic activities of cytochrome P450 IIIA4 expressed in *Saccharomyces cerevisiae*. Biochemistry 29:11280-11292.

20. Wong G, Kawajiri K, Negishi M 1987 Gene family of male-specific testosterone 16 α -hydroxylase (C-P-45016a) in mouse liver: cDNA sequences, neonatal imprinting, and reversible regulation by androgen. Biochemistry 26:8683-8690

21. Sugita O, Sassa S, Miyairi S, Fishman J, Kubota I, Noguchi T and Kappas A 1988 Cytochrome P450_{C-M/F}, a new constitutive form of microsomal cytochrome P450 in male and female rat liver with estrogen 2- and 16 α -hydroxylase activity. *Biochemistry* 27:678-686.
22. Suto A, Bradlow HL, Wong GYC, Osborne MP and Telang NT 1993 Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. *Breast Cancer Res Treatment* 27:193-202.
23. Suto A, Bradlow HL, Kubota T, Kitajima M, Wong GYC, Osborne MP and Telang NT 1993 Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agents. *Steroids* 58:215-219.
24. Vickers PJ, Dufresne MJ and Cowan KH 1989 Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. *Mol Endocrinol* 3:157-164.
25. Gotoh 1992 Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analysis of amino acid and coding nucleotide sequence. *J Biol Chem* 267:83-90.
26. Matsunaga E, Zeugin T, Zanger UM, Aoyama T, Meyer UA, Gonzalez FJ 1990 Sequence requirements for cytochrome P-450IID1 catalytic activity. *J Biol Chem* 265:17197-17201
27. Jenson J, Serup P, Karlsen C, Nielsen TF and Madsen OD 1996 mRNA profiling of rat islet tumors reveals Nkx6.1 as a β -cell-specific homeodomain transcription factor. *J Biol Chem* 271:18749-18758
28. Gierthy JF, Lincoln II DW, Kampeik SJ, Dickerman HW, Bradlow HL, Niwa T and Swanek GE 1988 Enhancement of 2- and 16 α -estradiol hydroxylation in MCF-7 human breast cancer cells by 2,3,7,8-tetrachlorobenzo-*p*-dioxin. *Biochem Biophys Res Comm* 157:515-520
29. Roeder RG and Chiang C-M 1993 Expression and purification of general transcription factors by FLAG epitope-tagging and peptide elution *Peptide Res* 6:2
30. Matsunaga E, Umeno M, Gonzalez FJ 1990 The rat p450 IID subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme-binding region of the cytochrome p450 active site. *Mol Evol* 30:155-169
31. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ 1989 The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and

identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. *Am J Hum Genet* 45:889-904

32. Heim MH, Meyer UA 1992 Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. *Genomics* 14:49-58

33. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA 1990 Multiple mutations of the human cytochrome p450IID6 gene in poor metabolizers of debrisoquine. *J Biol Chem* 265:17209-17214

34. Broly F, Gaedigk A, Heim M 1991 Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. *DNA Cell Biol* 10:545-558

35. Panserat S, Mura C, Gerard N, Vincent-viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R 1994 DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolizers. *Hum Genet* 94:401-406

36. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F and Ingelman-Sundberg M 1993 Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. *Proc Natl Acad Sci USA* 90:11825-11829

APPENDIX

Grant Number DAMD17-94-J-4441

AT-1

Induction of Aberrant Hyperproliferation and Tumorigenic Transformation by C-myc Oncogene in Mouse Mammary Epithelial Cells.

Cell Line	Status of Transformation	
	in vitro	in vivo
	Anchorage-independent growth (%CFE) ^a	tumorigenicity ^b
MMEC	ND	-
MMEC/myc ₃	12.8 ± 3.8	7/10
MMEC/myc ₃ -Pr ₁	26.8 ± 3.8	10/10

$$^a \frac{\text{Number of colonies}}{\text{Initial seeding density}} \times 100$$

$$^b \frac{\text{Number of tumors}}{\text{Number of transplant sites}}$$

AT-2

C-myc Oncogene-Mediated Alteration in Estradiol Metabolism and in Hormone Receptor Status

Cell Line	E2 Metabolism ^a (C2/C16 α -hydroxylation)	Receptor Protein Content ^b (fmol per 1.0 x 10 ⁶ cells)	
		ERP	PRP
MMEC	5.4 \pm 0.4	11.9 \pm 0.5	0.8 \pm 0.3
MMEC/myc ₃	2.7 \pm 0.4	8.8 \pm 1.5	2.4 \pm 0.4
MMEC/myc ³ -Pr ₁	1.6 \pm 0.6	2.9 \pm 0.5	1.6 \pm 0.1

^a determined by ³H₂O formation from [C2-³H]E₂ and [C16 α -³H]E₂

^b determined by dextran coated charcoal absorption (DCC) assay

AT-3

Metabolism of 17 β -Estradiol (E_2) in MMEC/myc₃-Pr₁ Cells

E_2 Metabolites	Relative Abundance ^{a,b} (Normalized per 1.0×10^7 cells)
E_1	1.465 ± 304
16 α -OHE ₁	206 ± 20
2-OHE ₁	799 ± 178
E_3	190 ± 14

^a determined by the RP-HPLC and GC-MS analysis of the culture medium

^b MMEC/myc₃-Pr₁ cells incubated with 1.0×10^{-8} M E_2 for 96 hours

AT-4

Ligand-mediated Upregulation of Proliferation and Hormone Receptor Status in MMEC/myc₃-Pr₁ Cells

E2 Treatment (nM)	Increase in cell number ^a (x10 ⁵)	Receptor Protein Content ^b (fmoles/1.0 x 10 ⁶ cells)	
		ERP	PRP
0.0	2.3 ± 0.6	2.1 ± 0.4	ND
0.1	2.8 ± 0.4	2.9 ± 0.5	ND
1.0	4.2 ± 0.5	8.0 ± 1.0	2.9 ± 0.2
10.0	4.4 ± 0.5	13.7 ± 3.1	3.5 ± 0.3

^a cells maintained in serum-free medium for 120 hours

^b determined by dextran-coated charcoal (DCC) absorption assay

AT-5

Modulation of Estradiol 2-Hydroxylation and Aberrant Hyperproliferation in Human Mammary Carcinoma MCF-7 Cells

Agent	2-hydroxylation of E ₂ ^a (% per 1.0 x 10 ⁶ cells)	Anchorage-Independent Growth (% CFE) ^b
EtOH		
(solvent control)	2.4 ± 0.4	15.3 ± 1.4
I3C	6.2 ± 0.3	5.0 ± 1.1
TAM	1.6 ± 0.1	3.7 ± 0.7
4-OH TAM	3.6 ± 0.2	1.8 ± 0.2
2-OHE ₁	ND	4.9 ± 2.9
16α-OHE ₁	ND	25.9 ± 2.0

^a determined from ³H₂O formation after a 48 hour incubation with [C₂-³H] E₂

^b
$$\frac{\text{Number of colonies}}{\text{Initial seeding density}} \times 100$$

AT-6

Breast Cancer Risk-Dependent Enhancement of Estradiol 16 α -Hydroxylation in Murine and Human Mammary Explant Cultures

Origin	Cancer Risk	Tissue Type ^a	Estradiol C16 α -hydroxylation (% per mg tissue) ^b
Murine	Low	NFS-MDE	0.16 \pm 0.05
	High	C3H-MDE	0.59 \pm 0.13
Human	Low	TDLU-LR	0.05 \pm 0.02
	High	TDLU-HR	0.31 \pm 0.05

^a Mammary ductal epithelium from low risk MFS strain, mammary ductal epithelium from high risk C3H strain, terminal duct lobular units from reduction mammoplasty, terminal duct lobular units from cancer mastectomy

^b determined from ³H₂O formation after a 48 hour incubation with [C16 α -³H] E₂

AT-7

Induction of Unscheduled DNA Synthesis and Aberrant Hyperproliferation by Estradiol Metabolites in Mouse Mammary Epithelial C57/MG Cells

Agent	Unscheduled DNA Synthesis (HU-insensitive ^3H -TdR uptake, cpm x 10^6 /mg DNA)	Anchorage-Independent Growth (% CFE) ^a
DMSO	12.5 ± 1.0	ND
(solvent control)		
DMBA	21.4 ± 2.2	24.0 ± 2.4
(positive control)		
E ₂	12.5 ± 1.0	1.0 ± 0.5
16 α -OHE ₁	22.0 ± 3.5	5.5 ± 0.3
2-OHE ₁	13.0 ± 0.9	0.3 ± 0.2

^a

$$\frac{\text{Number of colonies}}{\text{initial seeding density}} \times 100$$

Figure 1

Sites of oxidative metabolism in estradiol




Figure 2
Cyp2d-13 sequence

```

gaagtgttccaaagaaacccaaagagcagccgggcagcc ATG AGA CTG CCG ACC GGG GCT GAA CTG TGG CCC ATA 12
          M  R  L  P  T  G  A  E  L  W  P  I
GCC ATA TTC ACG GTC ATC TTC CTG ATT CTG GTG AAC CTG ATG CAC TGG CGC CAG CGC TGG ACT GCC 34
A  I  F  T  V  I  F  L  I  L  V  N  L  M  H  W  R  Q  R  W  T  A
CAC TAC CCT CCA GGC CCT ATG CCG TGG CCT GTG CTT GGG AAC CTG CTG CAC ATG GAC TTC CAG AAT 56
H  Y  P  P  G  P  M  P  W  P  V  L  G  N  L  L  H  M  D  F  Q  N
ATG CCA GCA GGC TTC CAA AAG CTG CGG GGT CGC TAT GGG GAC CTG TTC AGC CTA CAG CTG GCC TCT 78
M  P  A  G  F  Q  K  L  R  G  R  Y  G  D  L  F  S  L  Q  L  A  S
GAG TCA GTG GTT GTA CTA AAT GGG CTG ACG GCC CTG CGA GAG GCA CTG GTG AAA CAC AGC GAG GAC 100
E  S  V  V  V  L  N  G  L  T  A  L  R  E  A  L  V  K  H  S  E  D
ACT GCT GAC CGG CCA CCG CTG CAT TTC AAT GAC CTG CTG GGC TTT GGA CCA CGC TCT CAA GGT ATA 122
T  A  D  R  P  P  L  H  F  N  D  L  L  G  F  G  P  R  S  Q  G  I
GTC CTA GCA CGG TAT GGG CCT GCC TGG CGT CAG CAG CGG CGC TTC TCT GTG TCT ACC ATG CAC CAC 144
V  L  A  R  Y  G  P  A  W  R  Q  Q  R  R  F  S  V  S  T  M  H  H
TTT GGC CTG GGC AAG AAG TCA CTG GAG CAG TGG GTG ACT GAG GAG GCC AGA TGC CTC TGT GCC GCC 166
F  G  L  G  K  K  S  L  E  Q  W  V  T  E  E  A  R  C  L  C  A  A
TTC GCT GAC CAT ACT GGA CAC CCT TTC AGC CCT AAC ACC CTA TTG GAC AAA GCA GTG TGT AAC GTG 188
F  A  D  H  T  G  H  P  F  S  P  N  T  L  L  D  K  A  V  C  N  V
ATC GCG TCC CTC CTC TAT GCC TGC CGC TTT GAG TAC GAT GAC CCA CGC TTC ATC AGG CTA CTG GGC 210
I  A  S  L  L  Y  A  C  R  F  E  Y  D  D  P  R  F  I  R  L  L  G
TTG TTG AAG GAA ACT CTT AAG GAG GAA GCT GGA TTC CTA CCC ATG TTC CTG AAT GTG TTC CCG ATG 232
L  L  K  E  T  L  K  E  E  A  G  F  L  P  M  F  L  N  V  F  P  M
CTC CTG CGC ATC CCG GGG CTG GTT GGC AAG GTC TTC CCT GGG AAA AGG GCC TTT GTT ACC ATG TTG 254
L  L  R  I  P  G  L  V  G  K  V  F  P  G  K  R  A  F  V  T  M  L
GAT GAG CTG CTG GCT GAA CAC AAG ACG ACC TGG GAC CCT ACC CAG CCA CCC CGA GAT TTG ACT GAT 276
D  E  L  L  A  E  H  K  T  T  W  D  P  T  Q  P  P  R  D  L  T  D
GCC TTC CTG GCT GAG GTG GAG AAG GCC AAG GGG AAT CCT GAG AGC AGC TTC AAT GAT GAG AAC CTG 298
A  F  L  A  E  V  E  K  A  K  G  N  P  E  S  S  F  N  D  E  N  L
CGC ACG GTA GTG GGT GAC CTG TTC TCT GCA GGG ATG GTG ACC ACC TCA ACC ACA CTG TCC TGG GCC 320
R  T  V  V  G  D  L  F  S  A  G  M  V  T  T  S  T  T  L  S  W  A
CTG ATG CTC ATG ATC CTG CAT CCA GAT GTG CAG CGC CGA GTA CAA CAG GAA ATC GAT GAA GTC ATA 342
L  M  L  M  I  L  H  P  D  V  Q  R  R  V  Q  Q  E  I  D  E  V  I
GGG CAG GTG CAG TGT CCA GAG ATG GCA GAC CAG GCT CGC ATG CCC TAC ACC AAT GCT GTC ATT CAT 364
G  Q  V  Q  C  P  E  M  A  D  Q  A  R  M  P  Y  T  N  A  V  I  H
GAG GTG CAG CGC TTT GCA GAC ATT CTC CCT CTT GGT GTA CCT CAC AAG ACT TCT CGT GAC ATT GAA 386
E  V  Q  R  F  A  D  I  L  P  L  G  V  P  H  K  T  S  R  D  I  E
CTA CAG GGC TTC CTT ATC CCT AAG GGG ACG ACC CTC ATC ACC AAC CTG TCC TCC CGC CTA AAA GAT 408
L  Q  G  F  L  I  P  K  G  T  T  L  I  T  N  L  S  S  A  L  K  D
GAG ACT GTC TGG GAG AAG CCC CTC TGC TTC CAT CCT GAA CAC TTC CTG GAT GCC CAG GGC CAC TTT 430
E  T  V  W  E  K  P  L  C  F  H  P  E  H  F  L  D  A  Q  G  H  F
GTG AAG CCT GAG GCC TTC ATG CCA TTC TCA GCA GGC CGC AGA TCA TGC CTG GGG GAG CCC CTG GCC 452
V  K  P  E  A  F  M  P  F  S  A  G  R  R  S  C  L  G  E  P  L  A
CGC ATG GAG CTC TTC CTC TTC TTC ACC TGC CTC CTG CAG CGC TTT AGC ATC TCA GTG CCC GAT GGA 474
R  M  E  L  F  L  F  F  T  C  L  L  Q  R  F  S  I  S  V  P  D  G
CAG CCC CAG CCC AGC GAC CAT GGC GTC TTT AGG GCT CTG ACA ACC CCA TGC CCC TAC CAG CTC TGT 496
Q  P  Q  P  S  D  H  G  V  F  R  A  L  T  T  P  C  P  Y  Q  L  C
GCT TTG CCC CGC TAA  gaggatgtatgacatctcactcactgtgcttgctggggtcctaagtgtgcaataaagcattttac 500
A  L  P  R  *

```

Figure 3

**Partial alignment of *Cyp2-d13* with rat CYP2D4 (P450-CMF3)
and mouse *Cyp2-d9* (testosterone 16 α -hydroxylase)**


	10	20	30	40	50	60
Cyp2-d13	TGCGGTGGTG	CATGAGGTGC	AGCGCTTTGC	AGACATTCTC	CCTCTTGGTG	TACCTCACAA
CYP2D4	TGctGTcaTc	CATGAGGTGC	AGCGCTTTGC	AGACATTCTC	CCTCTTGGTG	TgCCTCACAA
	^^^v^^vv^v	^^^^^^^^	^^^^^^^^	^^^^^^^^	^^^^^^^^	^v^^^^^^^^
Cyp2-d9	TGctGTcaTt	CATGAGGTGC	AGCGCTTTGg	gGACATTgTt	CCagTgaaTt	TgCCaCgCAt
	^^^v^^vv^v	^^^^^^^^	^^^^^^^^v	v^^^^^^^v^v	^^vv^vvv^v	^v^^^v^v^v
	70	80	90	100	110	120
Cyp2-d13	GACTTCTCGT	GACATTGAAC	TACAGGGCTT	CCTTATCCCT	AAGGGACGAC	CCTCATCACC
CYP2D4	GACTTCTCGT	GACATTGAAg	TgCAGGGCTT	CCTTATCCCT	AAGGGACaAC	CCTCATCACC
	^^^^^^^^	^^^^^^^^v	^v^^^^^^^^	^^^^^^^^	^^^^^^^v^^	^^^^^^^^
Cyp2-d9	cACaagTCaT	GACATTGAAg	TgCAGGaCTT	CCTcATCCCC	AAGGGACGAt	CCTCcTCcCC
	v^^vvv^^v^	^^^^^^^^v	^v^^^^^v^^	^^^v^^^^^^v	^^^^^^^^^v	^^^v^^^v^^
	130	140	150	160		
Cyp2-d13	AACCTGTCCT	CCGCGCTAAA	AGATGAGACT	GTCTGGGAGA	AGCCCTCT	
CYP2D4	AACCTGTCCT	CaGtGCTgAA	gGATGAGACc	GTCTGGGAGA	AGCCC-CT	
	^^^^^^^^	^v^v^^^v^^	v^^^^^^^^v	^^^^^^^^	^^^^ ^	
Cyp2d-9	AACaTGTCCT	CCatGCTgAA	AGATGAGtCT	GTCTGGGAGA	AGCCC-CT	
	^^^v^^^^^^	^^vv^^^v^^	^^^^^^^v^^	^^^^^^^^	^^^^ ^	

Figure 4

Partial Amino acid alignment of the *Cyp2d* subfamily

	<u>SRS-5</u>									
	370	380	390	400	410	420				
2d-13	AVVHEVQRFA	DILPLGVPHK	TSRDIELQGF	LIPKGTTLIT	NLSSALKDET	VWEKPLCFHP				
2d-9	i	g	v vnl ri	h v d	i lp	m m s				r
2d-10	i	g	a nl ri	v d	si p	m v				r
2d-11	i	g	tl h chasq	vvtftqv d	vt s	p v g				r
			c							
	430	440	450	460	470	480				
2d-13	EHFLDAQGHF	VKPEAFMPFS	AGRRSCLGEP	LARMELFLFF	TCLLQRFSIS	VPDGQPQPSD				
2d-9			a		f					n
2d-10					h f	n			r	rn
2d-11			h	a						n
	<u>SRS-6</u>									
	490	500								
2d-13	HGVFRALTTP	CPYQLCASPR								
2d-9	s ygi va	s vv								
2d-10	l pfpva	y vm								
2d-11	yr haipva	f								


Figure 5
***Cyp2d-13* expression is elevated**
in mammary tumors and tumor-derived cell lines



A: MMEC
 B: RIII/MG
 C: RIII/Pr1
 D: RIII normal mammary gland
 E: RIII primary mammary tumor

Figure 6

***Cyp2d-13* is primarily confined
to the liver in normal tissues**



M: Mammary Gland
O: Ovary
L: Liver
K: Kidney
I: Intestine (Duodenum)
A: Adrenal
H: Heart
U: Uterus
B: Brain
S: Spleen

Figure 7


Immunocytochemical detection of P450 2d-13
in transfected 293T and COS-1 cells

Antiserum

FLAG

422 (α -SRS-1)


A



B

CMV-2d-13
(293T)

C



D

CMV
(293T)

E



CMV-2d-13
(COS-1)

Figure 8
Immunocytochemical detection of P450 2d-13
in tumor-derived RIII/Pr1 cells

RIII/Pr1 (α -SRS-1)



MMEC (α -SRS-1)



Figure 9

CYP2D6 Polymorphisms

